First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Clinical trial NCT03653546 · COMPLETED

Trial details

NCT number: NCT03653546
Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd.
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer EGFR Gene Mutation Brain Metastases

Start date: 2018-10-29
Primary completion: 2022-07-12
Enrollment: 492

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.